VOLITIONRX LTD
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
VNRX$0.18-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States Dollars)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| $ | $ | |
| Operating Activities | ||
| Net loss | (21,400,758) | (26,877,374) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 817,542 | 855,947 |
| Amortization of operating lease right-of-use assets | 169,273 | 194,036 |
| Loss on disposal of fixed assets | 34,693 | 15,913 |
| Stock-based compensation | 942,805 | 1,823,811 |
| Gain on change in fair value of warrant liability | (30,424) | (249,845) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | (168,625) | (2,402) |
| Accounts receivable | (69,992) | (34,441) |
| Other current assets | (24,064) | (45,785) |
| Deferred revenue, current and non-current | (106,600) | - |
| Accounts payable and accrued liabilities | (416,167) | 12,128 |
| Management and directors’ fees payable | (34,774) | (11,137) |
| Right-of-use assets operating leases liabilities | (174,758) | (191,586) |
| Net Cash Used In Operating Activities | (20,461,849) | (24,510,735) |
| Investing Activities | ||
| Purchases of property and equipment | (204,898) | (775,027) |
| Purchase of License | (171,095) | - |
| Net Cash Used In Investing Activities | (375,993) | (775,027) |
| Financing Activities | ||
| Net proceeds from issuances of common stock | 6,565,422 | 25,795,654 |
| Tax withholdings paid related to stock-based compensation | (57,127) | (80,231) |
| Common stock repurchased | - | (31,772) |
| Proceeds from grants repayable | - | 27,052 |
| Proceeds from long-term debt | 754,457 | 216,908 |
| Payments on long-term debt | (831,542) | (680,325) |
| Payments on grants repayable | (28,213) | - |
| Payments on finance lease obligations | (35,621) | (35,071) |
| Net Cash Provided By Financing Activities | 6,367,376 | 25,212,215 |
| Effect of foreign exchange on cash | (845,371) | 15,244 |
| Net change in cash and cash equivalents | (15,315,837) | (58,303) |
| Cash and cash equivalents – beginning of the period | 20,729,983 | 10,867,050 |
| Cash and cash equivalents – End of Period | 5,414,146 | 10,808,747 |
| Supplemental Disclosures of Cash Flow Information | ||
| Interest paid | 247,871 | 163,623 |
| Non-Cash Financing Activities | ||
| Common stock issued upon cashless exercises of stock options and settlement of vested RSUs | 578 | 308 |
| Offering costs from issuance of common stock | 245,107 | 239,772 |
| Fair value of warrants issued in connection with public offering | - | 366,960 |
| Common stock issued for License rights | 125,258 | - |
| Non-cash note payable | 294,603 | 356,258 |
| (The accompanying notes are an integral part of these condensed consolidated financial statements) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.